View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar Urológiai Klinika Budapest Üllői út 78/b 1082
Restricted access

A szerző összefoglalja a benignus prostata-hyperplasiában jelenleg alkalmazott gyógyszereket. A növényi kivonatokkal szerzett tapasztalatok két évtizedes múltra tekintenek vissza, alkalmazásuk a benignus prostata-hyperplasia iniciális fázisában javasolt. A hormonális hatású 5-alfa-reduktáz finasterid jelentős, bár csak több év-hónap alatt kialakuló prostatavolumen-redukció a vizelési zavarok mechanikus komponensét befolyásolja kedvezően. Indikációja főleg a 40 g feletti prostatavolumen esetén áll fenn. Az alfa-receptor-gátlók a hólyagnyakra ható, rövid terápiás idejű relaxáns hatásokkal a prostata-hyperplasia dinamikus komponensére hatnak, alkalmazásuk indokolt minden benignus prostata-hyperplasia esetében, függetlenül a prostatavolumentől. Több-kevesebb hypotoniás mellékhatással számolni kell. Az utóbbi időben az 5-foszfodiészteráz-gátlók kedvező hatását is leírták, illetve az is nyilvánvalóvá vált, hogy az alfa-blokkolókkal kezelt beteg szexuális aktivitása is fokozódik.

  • Berges, R. R., Windeler, J., Trampisch H. és mtsai: Randomised, placebo-controlled, double blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet, 1995, 345 , 1529–1532.

    Trampisch H. , 'Randomised, placebo-controlled, double blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia ' (1995 ) 345 Lancet : 1529 -1532.

    • Search Google Scholar
  • Carraro, J. C., Raynaud, J. P., Koch, G. és mtsai: Comparison of phytotherapy (Permixon) with finasterid in the treatment of benign prostatic hyperplasia: a randomized international study of 1.089 patients. Prostate, 1996, 29 , 231–240.

    Koch G. , 'Comparison of phytotherapy (Permixon) with finasterid in the treatment of benign prostatic hyperplasia: a randomized international study of 1.089 patients ' (1996 ) 29 Prostate : 231 -240.

    • Search Google Scholar
  • Debruyne, F.: Phytotherapy (LSESR) vs an α-blocker for treatment of lower urinary tract symptoms secondary to benign prostatic enlargement: A randomized comparative study. J. Urol., 2001, 165 , 381–382.

    Debruyne F. , 'Phytotherapy (LSESR) vs an α-blocker for treatment of lower urinary tract symptoms secondary to benign prostatic enlargement: A randomized comparative study ' (2001 ) 165 J. Urol. : 381 -382.

    • Search Google Scholar
  • Kuznetsow, D. D., Gerber, G. S., Burstein, J. D.: Randomized, double blind, placebo-controlled study of saw palmetto in men with lower urinary tract symptoms (LUTS). J. Urol., 2001, 165 , 263.

    Burstein J. D. , 'Randomized, double blind, placebo-controlled study of saw palmetto in men with lower urinary tract symptoms (LUTS) ' (2001 ) 165 J. Urol. : 263 -.

    • Search Google Scholar
  • Bach, D.: Placebokontrollierte Langzeittherapie-studie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe B., 2000, 40 , 437–443.

    Bach D. , 'Placebokontrollierte Langzeittherapie-studie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden ' (2000 ) 40 Urologe B. : 437 -443.

    • Search Google Scholar
  • Romics I.: Bazoton ® – Einfluss des Dosierungsschemas auf das Therapieergebnis. In: Benigne Prostatahyperplasie. Szerk.: Boos, G. pmi Verlagsgruppe GmbH, Frankfurt, 1994, 25–30.

    Romics I. , '', in Benigne Prostatahyperplasie , (1994 ) -.

  • Kim Il Chun, Chang Soo Hyuk, Kim Kun Byoung és mtsa: Long-term results of medical treatment in benign prostatic hyperplasia. Urology, 2006, 68 , 1015–1019.

    Byoung K.K. , 'Long-term results of medical treatment in benign prostatic hyperplasia ' (2006 ) 68 Urology : 1015 -1019.

    • Search Google Scholar
  • Vaughan, D., Imperato-McGinley, J., McConnel, J. és mtsai: Long-term (7 to 8 year) experience with finasteride in benign prostatic hyperplasia. Urology, 2002, 60 , 1040–1044.

    McConnel J. , 'Long-term (7 to 8 year) experience with finasteride in benign prostatic hyperplasia ' (2002 ) 60 Urology : 1040 -1044.

    • Search Google Scholar
  • Caine, M., Perlberg, S., Meretyk, S.: A placebocontrolled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br. J. Urol., 1978, 50 , 551–554.

    Meretyk S. , 'A placebocontrolled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction ' (1978 ) 50 Br. J. Urol. : 551 -554.

    • Search Google Scholar
  • Gormley, G. J., Stoner, E., Bruskewitz, R. C. és mtsai: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med., 1992, 327 , 1185–1191.

    Bruskewitz R. C. , 'The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group ' (1992 ) 327 N. Engl. J. Med. : 1185 -1191.

    • Search Google Scholar
  • Kirby, R. S.: Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Scand. J. Urol. Nephrol., 1995, 168 , 29–33.

    Kirby R. S. , 'Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia ' (1995 ) 168 Scand. J. Urol. Nephrol. : 29 -33.

    • Search Google Scholar
  • Carruthers, S. G.: Adverse effects of alpha 1-adrenergic blocking drugs. Drug Saf., 1994, 11 , 12–20.

    Carruthers S. G. , 'Adverse effects of alpha 1-adrenergic blocking drugs ' (1994 ) 11 Drug Saf. : 12 -20.

    • Search Google Scholar
  • Brawer, M. K., Lin, D. W., Williford, W. O. és mtsai: Effect of finasterid and/or terazosin on serum PSA: results of VA Cooperative Study 359. Prostate, 1999, 39 , 234–239.

    Williford W. O. , 'Effect of finasterid and/or terazosin on serum PSA: results of VA Cooperative Study 359 ' (1999 ) 39 Prostate : 234 -239.

    • Search Google Scholar
  • Roehrborn, C. G.: Efficacy and safety of once-daily alfuzosin in the teatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology, 2001, 58 , 953–959.

    Roehrborn C. G. , 'Efficacy and safety of once-daily alfuzosin in the teatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial ' (2001 ) 58 Urology : 953 -959.

    • Search Google Scholar
  • Bendix Holme, J., Christensen, M. M., Rasmussen, P. C.: 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand. J. Urol. Nephrol., 1994, 28 , 77–82.

    Rasmussen P. C. , '29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study ' (1994 ) 28 Scand. J. Urol. Nephrol. : 77 -82.

    • Search Google Scholar
  • Kirby, R. S.: Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Scand. J. Urol. Nephrol., 1995, 168 , 29–33.

    Kirby R. S. , 'Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia ' (1995 ) 168 Scand. J. Urol. Nephrol. : 29 -33.

    • Search Google Scholar
  • Wilt, T. J., MacDonald, R., Nelson, D.: Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J. Urol., 1998, 54 , 367–373.

    Nelson D. , 'Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects ' (1998 ) 54 J. Urol. : 367 -373.

    • Search Google Scholar
  • Gleason, D. M., Bottaccini, M. R.: Effect of terazosin on urine storage and voiding in the aging male with prostatism. Neurourol. Urodyn., 1994, 13 , 1–12.

    Bottaccini M. R. , 'Effect of terazosin on urine storage and voiding in the aging male with prostatism ' (1994 ) 13 Neurourol. Urodyn. : 1 -12.

    • Search Google Scholar
  • Blake-James, B. T., Rashidian, A., Ikeda, Y. és mtsa: The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int., 2007, 99 , 85–96.

    Ikeda Y. , 'The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis ' (2007 ) 99 BJU Int. : 85 -96.

    • Search Google Scholar
  • Kaplan, S. A.: The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Eur. Urology, 2007, 52 , 1523–1527.

    Kaplan S. A. , 'The motion: PDE5 inhibitors will have a significant role in the treatment of BPH ' (2007 ) 52 Eur. Urology : 1523 -1527.

    • Search Google Scholar
  • Barqawi, A. B., Mayers J., O’Donnell, C. és mtsai: The effect of α-blocker and 5α-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU Int., 2007, 100 , 853–857.

    O’Donnell C. , 'The effect of α-blocker and 5α-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms ' (2007 ) 100 BJU Int. : 853 -857.

    • Search Google Scholar
  • Romics I.: Vizeletürítési zavarok és a szexuális diszfunkció. Magy. Urol., 2006, 18 , 248–252.

    Romics I. , 'Vizeletürítési zavarok és a szexuális diszfunkció ' (2006 ) 18 Magy. Urol. : 248 -252.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 96 0 4
Feb 2021 83 0 4
Mar 2021 88 0 2
Apr 2021 52 0 1
May 2021 49 0 3
Jun 2021 33 1 2
Jul 2021 0 0 0